Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 5, 2010, Pages 1329-1333

  Tanwar, Lalita ^a   Piplani, Honit ^a   Sanyal, S N ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Apoptosis; BrdU; Etoricoxib; PCNA; Proliferation

Indexed keywords

EID: 79955949250     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Baker AJ, Mooney A, Hughes J, et al (1994). Mesengial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesengial proliferative nephritis. J Clin Invest, 94, 2105-16.
2. Biasco G, Paganelli GM, Santucci R, et al (1994). Methodological problems in the use of rectal cell proliferation as a biomarker of colorectal cancer risk. J Cell Biochem, 19, 55-60.
3. Bolton WE, Mikulka WR, Healy CG, et al (1992). Expression of proliferation associated antigens in the cell cycle of synchronized mammalian cells. Cytometry, 13, 117-26.
4. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the priniciple of protein-dye binding. Anal Biochem, 72, 248-54.
5. Chan TA (2002). Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol, 3, 166-74.
6. Evan GI, Vousdan HK (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-8.
7. Hanif R, Pittas A, Feng Y, et al (1996). Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandinindependent pathway. Biochem Pharmacol, 52, 237-45.
8. Heitman DW, Grubbs BG, Heitman TO, et al (1983). Effects of 1,2-dymethylhydrazine treatment and feeding regimen on rat colonic epithelial cell proliferation. Cancer Res, 43, 1153-62.
9. Kanwar SS, Vaiphei K, Nehru B, et al (2008). Antioxidative effects of non-steroidal anti-inflammatory drugs during the initiation stages of experimental colon carcinogenesis in rats. J Environ Pathol Toxicol Oncol, 27, 89-100.
10. Kelman Z (1997). PCNA: Structure, functions and interactions. Oncogene, 14, 2796-805.
11. Kerr JFR, Winterford CM, Harmon BV (1994). Apoptosis. Its significance in cancer and cancer therapy. Cancer, 73, 2013-26.
12. Leahy KM, Ornberg RL, Wang Y, et al (2002). Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res, 62, 625-31.
13. Li J, Chen X, Dong X, et al (2006). Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells. J Gastroenterol Hepatol, 21, 1814-20.
14. Lowe SW, Lin AW (2000). Apoptosis in cancer. Carcinogenesis, 21, 485-95.
15. Ma QY, Williamson KE, Rowlands BJ (2002). Variability of cell proliferation in the proximal and distal colon of normal rats and rats with dimethylhydrazine induced carcinogenesis, World J Gastroenterol, 8, 847-52.
16. Marnett LJ, DuBois RN (2002). COX-2: A target for colon cancer prevention. Annu Rev Pharmacol Toxicol, 42, 55-80.
17. Mouille B, Robert V, Blachier F (2004). Adaptive increase of ornithine production and decrease of ammonia metabolism in rat colonocytes and hyperproteic diet ingestion. Am J Physiol, 287, 344-51.
18. Paunesku T, Mittal S, Protic M, et al (2001). Proliferating cell nuclear antigen (PCNA): Ringmaster of the genome. Int J Radiat Biol, 77, 1007-21.
19. Qiao L, Kozoni V, Koutsos MI, et al (1995). Eicosanoids increase the proliferation rate in human colon carcinomas cell lines and mouse colon cells. Biochim Biophys Acta, 1258, 215-23.
20. Qiao L, Shiff SJ, Rigas B (1997). Sulindac sulfide induces several subpopulations of colon cancer cells, defined by PCNA/Ki-67 and DNA strand breaks. Biochim Biophys Acta, 1359, 222-32.
21. Richards TC (1977). Early changes in the dynamics of crypt cell populations in mouse colon following administration of 12,-dimethylhydazine. Cancer Res, 37, 1680-5.
22. Riendeau D, Percival MD, Brideau C, et al (2001). Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther, 296, 558-66.
23. Roediger WEW, Truelove SC (1979). Method of preparing isolated colonic epithelia cells (colonocytes) for metabolic studies. Gut, 20, 484-8.
24. Saini MK, Sharma P, Kaur J, et al (2009). The cycloxygenase-2 inhibitor Etoricoxib is a potent chemopreventive agent of colon carcinogenesis in the rat model. J Environ Pathol Toxicol Oncol, 28, 39-46.
25. Sambrook J, et al (1998). Molecular Cloning: A laboratory manual, 2nd ed. Cold spring harber laboratory press, cold spring harber, New York. 192 pp.
26. Sharma P, Kaur J, Sanyal SN (2010). Effect of etoricoxib, a Cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethylhydrazine induced colon carcinogenesis in rat model. Nutr Hosp, 25, 39-48.
27. Stark LA, Reid K, Sansom OJ (2007). Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis, 28, 968-78.
28. Taketo MM (1998). Cox-2 and colon cancer. Inflamm Res, 47, 112-6.
29. Tanwar L, Vaish V, Sanyal SN (2009). Chemoprevention of 1,2-dimethylhydrazine-induced colon carcinogenesis by a non-steroidal anti-inflammatory drug, Etoricoxib, in rats: inhibition of nuclear factor kB. Asian Pac J Cancer Prev, 10, 1141-6.
30. Wyllie AH, Kerr JFR, Currie Arm (1972). Cell death: The significance of apoptosis. Int Rev Cytol, 68, 251-306.
31. Yao M (2004). Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer, 90, 712-9.